{"product_id":"p21-p021","title":"P21 (P021)","description":"\u003ch3\u003eP21 (P021)\u003c\/h3\u003e\n\u003ch3\u003e1. Basic Overview\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eP21, also known as P021, is a synthetic lipophilic peptide mimetic derived from the active domain of Ciliary Neurotrophic Factor (CNTF). It was developed by Dr. Khalid Iqbal’s research team for neurodegeneration research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAmino Acid Sequence: Ac-DGGLAG-NH₂\u003c\/li\u003e\n\u003cli\u003eMolecular Weight: 529.55 Da\u003c\/li\u003e\n\u003cli\u003eCAS: No official universal CAS registry number (novel research peptide)\u003c\/li\u003e\n\u003cli\u003eForm: Lyophilized white crystalline powder\u003c\/li\u003e\n\u003cli\u003eCore Feature: Can cross the blood-brain barrier (BBB) in preclinical animal models. It replicates CNTF’s neuroprotective benefits\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003ewithout severe weight loss\/cachexia side effects\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003ecaused by full-length CNTF protein.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e2. Mechanism of Action\u003c\/h3\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eUpregulate BDNF Production\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eStimulates elevated Brain-Derived Neurotrophic Factor (BDNF) expression within the hippocampus. BDNF supports neuronal survival, dendritic spine growth and synaptic plasticity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInhibit GSK-3β Kinase\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eSuppresses activity of glycogen synthase kinase 3-beta. This reduces abnormal hyperphosphorylation of tau protein, one major hallmark neurofibrillary tangle pathology in Alzheimer’s disease.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReduce Amyloid Beta Toxicity\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eModulates APP processing, lowering the generation and aggregation of Aβ peptide in preclinical AD models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePromote Hippocampal Neurogenesis\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eSupports the generation of new neurons in the dentate gyrus, a brain region critical for memory formation and learning.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eModulate CNTF\/LIF Pathway\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eSelectively activates neurotrophic signaling while avoiding the LIF-mediated metabolic wasting effects associated with native CNTF.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch3\u003e3. Main Research Applications\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eAlzheimer’s disease \u0026amp; tauopathy preclinical animal models\u003c\/li\u003e\n\u003cli\u003eHippocampal neurogenesis, memory and cognitive function research\u003c\/li\u003e\n\u003cli\u003eSynaptic plasticity and neuronal regeneration experiments\u003c\/li\u003e\n\u003cli\u003eNeuroinflammation and neurodegeneration pathway studies\u003c\/li\u003e\n\u003cli\u003eTraumatic brain injury (TBI) neuronal recovery models\u003c\/li\u003e\n\u003cli\u003eComparative research: P21 vs full-length CNTF; P21 combined with nootropic peptides\u003c\/li\u003e\n\u003cli\u003eAge-related cognitive decline and brain senescence laboratory studies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e4. Reconstitution Instructions (Lyophilized Vial)\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eCommon specification: \u003c\/span\u003e\u003cstrong\u003e5mg \/ 10mg per vial\u003c\/strong\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003eLet peptide vial reach room temperature; disinfect rubber stopper with alcohol wipe.\u003c\/li\u003e\n\u003cli\u003eSlowly inject Bacteriostatic Water along the inner glass wall. Avoid direct impact onto lyophilized powder.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cdiv\u003eRecommended mixing scheme: 10mg powder + 2mL BAC water → Concentration = 5 mg\/mL\u003c\/div\u003e\n\u003col start=\"3\"\u003e\n\u003cli\u003eGently rotate the vial to dissolve powder.\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eDO NOT shake violently to prevent peptide structural degradation.\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eQualified solution is clear and colourless.\u003c\/li\u003e\n\u003cli\u003eStorage Requirements\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cul\u003e\n\u003cli\u003eUnreconstituted lyophilized powder: Hermetically sealed, stored at -20°C, protected from light. Stable for up to 24 months.\u003c\/li\u003e\n\u003cli\u003eReconstituted peptide solution: Refrigerate 2°C ~ 8°C, stable within 28 days.\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eDo not freeze reconstituted liquid; repeated freeze-thaw impairs activity.\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e5. Research Administration Protocols\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eTwo common experimental routes in preclinical research: Subcutaneous injection \u0026amp; Intranasal delivery.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e1) Subcutaneous Injection (Widely used)\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eLow starting tolerance dose:\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e100–250 mcg once daily\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eStandard experimental dose:\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003e300–500 mcg once daily\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eHigh experimental dose: Up to 750 mcg once daily (limited long-term safety data)\u003c\/li\u003e\n\u003cli\u003eInjection site: Lower abdomen or anterior thigh; rotate injection positions regularly.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e2) Intranasal Administration (Preferred for CNS-targeted research)\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eIntranasal delivery bypasses systemic circulation and directly targets brain tissue.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eWorking concentration: 1–2 mg\/mL reconstituted solution\u003c\/li\u003e\n\u003cli\u003eDosage reference: 50–200 mcg once daily via nasal instillation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eReference Experimental Cycle\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eContinuous administration for \u003c\/span\u003e\u003cstrong\u003e6–12 weeks\u003c\/strong\u003e\u003cspan\u003e, followed by a minimum 4-week washout period before starting a new research cycle.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003e6. Precautions \u0026amp; Observed Adverse Reactions\u003c\/h3\u003e\n\u003col\u003e\n\u003cli\u003ePure laboratory research compound. Not authorized for human therapeutic use.\u003c\/li\u003e\n\u003cli\u003eStrict aseptic technique required during reconstitution to prevent microbial contamination.\u003c\/li\u003e\n\u003cli\u003eDiscard solution immediately if turbidity, precipitation or discoloration appears.\u003c\/li\u003e\n\u003cli\u003eWithin standard experimental doses, systemic adverse reactions are rare. Occasional mild transient redness may appear at subcutaneous injection sites.\u003c\/li\u003e\n\u003cli\u003eAvoid concurrent use with other CNTF \/ neurotrophic mimetics unless specified by your research protocol.\u003c\/li\u003e\n\u003cli\u003eNo large-scale human clinical trial data exists. All results are limited to cell culture and rodent preclinical models.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr\u003e\n\u003ch3\u003eShort Version (For Product Page \/ Customer Direct Message)\u003c\/h3\u003e\n\u003ch3\u003eP21 (P021)\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eP21 (P021) is a BBB-permeable synthetic CNTF mimetic peptide. It elevates BDNF levels, inhibits GSK-3β, reduces tau hyperphosphorylation and promotes hippocampal neurogenesis. It is widely used in laboratory research focused on neurodegeneration, Alzheimer’s mechanisms, cognitive function and neuronal repair.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003eReconstitution\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eMix lyophilized powder with bacteriostatic water. Rotate gently; avoid violent shaking. Reconstituted solution must be refrigerated and used within 28 days.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3\u003eReference Research Dosage\u003c\/h3\u003e\n\u003cp\u003e\u003cspan\u003eSubcutaneous: 100–500 mcg once daily. Intranasal: 50–200 mcg once daily. Research cycles run 6–12 weeks with washout intervals.\u003c\/span\u003e\u003c\/p\u003e","brand":"我的商店","offers":[{"title":"5mg*10 vials","offer_id":53703814185260,"sku":null,"price":208.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0979\/1406\/1100\/files\/4d53ba72b08931f0fc6edbe5a0b45fe44756041fdc4d4a0649a567de8903df92.png?v=1786604499","url":"https:\/\/0rw2.com\/products\/p21-p021","provider":"0rw2.com","version":"1.0","type":"link"}